SynthesisCancer reports (Hoboken, N.J.)2026
The Effect of Interferon Type I Adjuvant Therapy on the Lifespan and Complications of Glioma Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis.
Synthesis in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe malignant glioma, as the most common and aggressive primary brain and spinal cord neoplasm, has shown limited responsiveness to available treatments, including tumor dissection, radiation, and chemotherapy. Thus, interferon type I, as a supplemental therapy, is added to the main therapies to overcome neoplasm resistance and prolong the patients' lifespan.
methodsTo clarify the effects of interferon adjuvant therapy on the lifespan and complications of glioma patients, we conducted a systematic review and meta-analysis by searching valid databases, scanning, and screening full texts based on a predefined protocol for the study.
resultsSeven studies were eligible for data synthesis and analysis. Lifespan, tumor progression, adverse events, and genetic factors were studied and analyzed in this systematic review and meta-analysis. The median overall survival (OS) and median progression-free survival (PFS) were increased as a result of the supplemental therapy. However, only the median OS was significantly improved (OS: HR = 0.74, 95% CI [0.58, 0.96]; p = 0.02/PFS: HR = 0.93, 95% CI [0.74, 1.18]; p = 0.56). Additionally, interferon adjuvant therapy could affect the toxic events of alkylating drugs; Flu-like and neurological events were significantly exacerbated (odds ratio = 3.31, 95% CI [1.20, 9.08]; p = 0.02, odds ratio = 6.15, 95% CI [2.20, 17.22]; p = 0.0005), while dermatological events were effectively alleviated as a result of interferon therapy (odds ratio = 0.29, 95% CI [0.10, 0.84]; p = 0.02). Variation of the hematological and hepatic events was not statistically significant (odds ratio = 1.06, 95% CI [0.52, 2.17]; p = 0.87, odds ratio = 1.06, 95% CI [0.67, 1.66]; p = 0.81).
conclusionDespite the development of a few adverse events, interferon type I supplemental therapy in combination with radiation and chemotherapy could significantly extend the lifespan of glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.